Demographic features and clinical characteristics of patients with Parkinson’s disease in Isfahan, Iran

  • Mehri Salari Isfahan Neurosciences Research Center, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Omid Mirmosayyeb Isfahan Neurosciences Research Center, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran
  • Masoud Etemadifar Isfahan Neurosciences Research Center, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Vahid Shaygannejad Isfahan Neurosciences Research Center, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Fariborz Khorvash Isfahan Neurosciences Research Center, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Mohammad Reza Najafi Isfahan Neurosciences Research Center, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Fereshteh Ashtari Isfahan Neurosciences Research Center, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Ahmad Chitsaz Isfahan Neurosciences Research Center, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Keywords: Parkinson Disease, Demographic, Iran

Abstract

Background: Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Its worldwide incidence rate varies between 18 and 418 cases per 100000 annually. This cross-sectional study was carried out with the aim to identify the clinical characteristics and demographic features of a huge number of patients with PD in Isfahan, Iran.Methods: The study was conducted on 987 patients with PD in Isfahan city and checklists were used to evaluate the demographic features and clinical characteristics of the patients.Results: The mean age of the patients at the time of sampling was 65.40 ± 11.90 years. The study results indicated that the rate of PD among men with 67.3% was twice that of women with 32.7%. The mean duration of the disease was 4.91 ± 4.60 years.Conclusion: This study showed a considerable rate of PD among the individuals in Isfahan city. In addition, the incidence ratio of men to women was more than the previous studies.

References

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5(6): 525-35.
2. Konitsiotis S, Bostantjopoulou S, Chondrogiorgi M, Katsarou Z, Tagaris G, Mavromatis I, et al. Clinical characteristics of Parkinson's disease patients in Greece: A multicenter, nation-wide, cross-sectional study. J Neurol Sci 2014; 343(1-2): 36-40.
3. Jankovic J, Tolosa E. Parkinson's disease and movement disorders. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
4. Muangpaisan W, Hori H, Brayne C. Systematic review of the prevalence and incidence of Parkinson's disease in Asia. J Epidemiol 2009; 19(6): 281-93.
5. Roohani M, Ali SG, Miri S. Demographic study of Parkinson’s disease in Iran: Data on 1656 cases. Iran J Neurol 2011; 10(1-2): 19-21.
6. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: A systematic review and meta-analysis. Mov Disord 2014; 29(13): 1583-90.
7. Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. Epidemiologic observations on Parkinson's disease: Incidence and mortality in a prospective study of middle-aged men. Neurology 1996; 46(4): 1044-50.
8. Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology 1999; 52(2): 302-8.
9. Fall PA, Axelson O, Fredriksson M, Hansson G, Lindvall B, Olsson JE, et al. Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community. J Clin Epidemiol 1996; 49(6): 637-41.
10. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999; 52(6): 1214-20.
11. Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009; 72(5): 432-8.
12. Elbaz A, Grigoletto F, Baldereschi M, Breteler MM, Manubens-Bertran JM, Lopez-Pousa S, et al. Familial aggregation of Parkinson's disease: A population-based case-control study in Europe. Europarkinson Study Group. Neurology 1999; 52(9): 1876-82.
13. Autere JM, Moilanen JS, Myllyla VV, Majamaa K. Familial aggregation of Parkinson's disease in a Finnish population. J Neurol Neurosurg Psychiatry 2000; 69(1): 107-9.
14. McCann SJ, LeCouteur DG, Green AC, Brayne C, Johnson AG, Chan D, et al. The epidemiology of Parkinson's disease in an Australian population. Neuroepidemiology 1998; 17(6): 310-7.
15. Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Fernandez-Crehuet Navajas R. Smoking and Parkinson's disease: Systematic review of prospective studies. Mov Disord 2004; 19(6): 614-21.
16. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: A review of the evidence. Eur J Epidemiol 2011; 26(Suppl 1): S1-58.
17. Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: A case-control study. Stroke 2006; 37(5): 1184-8.
18. Haghdoost AA, Rezazadeh-Kermani M, Sadghirad B, Baradaran HR. Prevalence of type 2 diabetes in the Islamic Republic of Iran: Systematic review and meta-analysis. East Mediterr Health J 2009; 15(3): 591-9.
19. Xu Q, Park Y, Huang X, Hollenbeck A, Blair A, Schatzkin A, et al. Diabetes and risk of Parkinson's disease. Diabetes Care 2011; 34(4): 910-5.
Published
2018-01-04
How to Cite
1.
Salari M, Mirmosayyeb O, Etemadifar M, Shaygannejad V, Khorvash F, Najafi MR, Ashtari F, Chitsaz A. Demographic features and clinical characteristics of patients with Parkinson’s disease in Isfahan, Iran. IJNL. 17(1):6-0.
Section
Original Article(s)